Fair Value Calculator Fair Value Calculator
EN DE

Ridgetech, Inc (RDGT) Fair Value & Analysis

Healthcare · US · Market cap $1.3M

RI Ridgetech, Inc logo Ridgetech, Inc RDGT · US
Price$1.41
Fair Value$1.19
Upside-15.4%
Quality33/100
Watch Ridgetech, Inc for free, get notified when fair value or trend changes. Watch for free
Evidence: High Range $0.8362 – $2.47 📤 Share as image

Fair value as of: Jul 19, 2026

From 20 valuation models · updated yesterday

Share price +3.7% over the past month.

Price vs Fair Value (12 months)

$760.50 $1.29 Fair Value $1.19 Jul 2025 Jul 2026

12‑month range $1.29 – $760.50 · fair‑value band $0.8362 – $2.47 · the $1.41 price screens above the $1.19 fair value. As of Jul 19, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Ridgetech, Inc (RDGT) currently trades at $1.41, while our model-based Fair Value estimate is $1.19, implying the stock looks roughly 15.4% overvalued today. We read business quality at 33/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Ridgetech, Inc generated revenue of $120M at a net margin of 10.4%. Revenue declined 11.7% year over year. It earns a return on equity of -8.0%. The balance sheet holds a net cash position of $2.4M. Fundamentals as of Jul 19, 2026

Our scenario range runs from $0.8362 (bear case) to $2.47 (bull case); at $1.41, the current price sits within that range. For context, the median of 10 Healthcare peers we cover trades at 33% fair-value upside, at -15%, RDGT screens richer than that median.

Key figures & financial health

Revenue (TTM) $120M
Revenue growth (YoY) -11.7%
Net margin 10.4%
Return on equity -8.0%
Free cash flow $633K FY2025
Operating margin -0.1%
More key figures
EPS (TTM) $-54.23
Net cash $2.4M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 19, 2026. TTM = trailing twelve months.

About the company

Ridgetech, Inc. operates as a wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China. It operates through three segments: Retail Drugstores, Online Pharmacy, and Drug Wholesale. The company engages in offline and online wholesale distribution of pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices, as well as convenience products comprising consumable, seasonal, and promotional items. It also distributes other healthcare products, such as health food, cosmetics, and daily necessities. The company was formerly known as China Jo-Jo Drugstores, Inc. and changed its name to Ridgetech, Inc. in February 2024. Ridgetech, Inc. is headquartered in Hangzhou, China.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Ridgetech, Inc reported revenue of $120M in FY2025 versus $133M in FY2021, a compound −2.6%/yr. Reported net income was $10.2M in FY2025.

Revenue −2.6%/yr
FY21 $133M
FY22 $164M
FY23 $149M
FY24 $155M
FY25 $120M
Net income
FY21 −$8.1M
FY22 −$3.2M
FY23 −$21.1M
FY24 −$4.2M
FY25 $10.2M

Is RDGT fairly valued? → Check now

📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog, it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "Ridgetech, Inc Fair Value". https://www.fairvalue-calculator.com/stock/RDGT

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).

Stock Price Fair Value vs Fair Value
JD Health International Inc JDHIY $5.33 $7.09 +33%
Alibaba Health Information Technology Limited ALBBY $8.27 $6.61 -20%
Raia Drogasil S.A RADL3 R$18.20 R$15.58 -14%
Yifeng Pharmacy Chain Co 603939 ¥19.75 ¥40.59 +106%
Clicks Group CLCGY $29.02 $34.57 +19%
Sugi Holdings SGIPF $16.29 $32.19 +98%
Corporativo Fragua, S.A. CGSBF $29.66 $40.13 +35%
DaShenLin Pharmaceutical Group 603233 ¥16.68 ¥19.21 +15%
LBX Pharmacy Chain Joint Stock Company 603883 ¥11.74 ¥10.57 -10%
Redcare Pharmacy NV SHPPF $64.80 $143.56 +122%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Ridgetech, Inc (RDGT) undervalued?
As of Jul 19, 2026, our model estimates a fair value of $1.19 versus a price of $1.41, about −15% (overvalued). Model-based estimate, not financial advice.
What is the fair value of RDGT?
Our model-based fair value for Ridgetech, Inc is $1.19 (as of Jul 19, 2026), built from audited fundamentals. The current price is $1.41.
What is the quality score of RDGT?
Ridgetech, Inc has a Quality Score of 33/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Ridgetech, Inc (RDGT)?
Ridgetech, Inc reported trailing-twelve-month revenue of about $120M (latest available figure, as of Jul 19, 2026).
What is the net profit margin of RDGT?
The net profit margin of Ridgetech, Inc is about 10.4%, meaning it keeps roughly 10.4% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

Free alert · no account needed

Tell me when Ridgetech, Inc reaches its Fair Value

Just your email, and we'll notify you when the price and Fair Value of Ridgetech, Inc materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.